Pharmaceuticals, Biotechnology and Life Sciences
Dr. Samuelson to Present First-of-its-Kind MIGS Prospective Study Demonstrating Statistical Improvements in Vision-Related Quality of Life from a Pivotal Trial…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being…
Preclinical data suggests multiple mechanisms of action for SM-88, including an increase in reactive oxygen species, alterations in autophagy and…
Preclinical and biomarker research data will be reported for U3-1402 (HER3 DXd ADC) in HER3 expressing cancers including combination with…
DUBLIN–(BUSINESS WIRE)–The “Biotechnology Markets in China” report has been added to ResearchAndMarkets.com’s offering. Biotechnology is a rapidly growing sector in…
GeneMe, a leading biotech company based in Gdańsk, Poland has developed “FRANKD” – a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement.
IMV is preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.
Stoke Therapeutics is on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020.
CanFite is working on Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the…
The company reported a net loss of $8.2 million, or $0.47 per share, for the three months ended March 31, 2020, compared to a net loss of $4.9 million, or $0.52 per share, for the same period in 2019. The company had $11.8 million in cash and cash equivalents as of March 31, 2020.